

# Comprehensive genomic profiling assays for oncological studies

## PanCancerIQ™: enhancing precision oncology

PanCancerIQ™ is a next-generation sequencing (NGS) assay that enables in-house comprehensive genomic profiling of tumor samples. It supports the identification of all relevant DNA and RNA variants implicated in various solid tumor types, along with biomarker content aligned with key guidelines and clinical trials.



By identifying genomic alterations driving cancer growth, mutations, insertions and deletions and other key measures for immuno-oncology, along with identifying oncogenic driver events to predict treatment response and resistance, PanCancerIQ advances the future of precision oncology throughout the preclinical and clinical stages.

## A complete genomic sequencing solution

PanCancerIQ services include:

- Variant call reporting
- Measuring tumor mutational burden
- Measuring microsatellite instability
- Genomic biomarker expression profiles/panels
- Bioinformatics services

Complex data is translated to identify tumor driver mutations, stratify patients based on therapeutic response and resistance mechanisms, link multiple data sets to clinical endpoints and identify potential predictive biomarkers.



Other essential and complementary analytical services, such as flow cytometry and ddPCR, aid in accelerating the development of precision oncology therapeutic innovations.

Other complementary services that can aid in accelerating the development of precision oncology therapeutics include:

- De novo assay development
- Cell-based assays for immune function and proliferation
- Immunogenicity testing
- NAb testing
- RCR/RCL detection and quantification

## Conclusion: in support of oncology clinical trial testing

PanCancerIQ aims to accelerate precision oncology studies through:

- 1 Screening of patients for recruitment in genomically informed trials
- 2 Supporting biomarker discovery for drug response and resistance studies
- 2 Monitoring tumor molecular evolution in recurrence or metastasis



This infographic has been created as part of a Bioanalysis Zone feature in association with Eurofins-Viracor BioPharma.